title: Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation.
abstract: Double unit cord blood (CB) transplantation (CBT) appears to augment engraftment despite only one unit engrafting in most patients. We hypothesized that superior unit quality, as measured by a higher percentage of viable cells postthaw, would determine the engrafting unit. Therefore, we prospectively analyzed 46 double-unit transplants postthaw using flow cytometry with modified gating that included all dead cells. Using a 75% threshold (mean viability minus 2 SD), 20% of units had low CD34+ cell viability, with viability varying according to the bank of origin. Further, in the 44 patients with single unit engraftment, CD34+ cell viability was higher in engrafting units (P=.0016). Although either unit engrafted if both had high CD34+ viability, units with <75% viability were very unlikely to engraft: in 16 patients who received one high and one low CD34+ viability unit, only 1 of 16 units with viability <75% engrafted (P=.0006). Further, in the single patient without engraftment of either unit, both had CD34+ viability <75%. Finally, poor CD34+ viability correlated with lower colony forming units (CFUs) (P=.02). Our data suggests one mechanism by which double unit CBT can improve engraftment is by increasing the probability of transplanting at least one unit with adequate viability and the potential to engraft.
authors.affiliation: Department of Pediatrics, Allogeneic Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA. scaradaa@mskcc.org
authors.forename: Andromachi
authors.initials: A
authors.lastname: Scaradavou
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Smith
authors.forename: Rebecca
authors.initials: R
authors.lastname: Hawke
authors.forename: Allison
authors.initials: A
authors.lastname: Schaible
authors.forename: Michelle
authors.initials: M
authors.lastname: Abboud
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Kernan
authors.forename: James W
authors.initials: JW
authors.lastname: Young
authors.forename: Juliet N
authors.initials: JN
authors.lastname: Barker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood* / Q000276:immunology; D001793:Blood Preservation; D002470:Cell Survival / Q000276:immunology; D002648:Child; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D005260:Female; D005312:Fetal Blood / Q000166:cytology / Q000276:immunology*; D005434:Flow Cytometry; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000628:therapy; D008223:Lymphoma / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011446:Prospective Studies; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018952:Antigens, CD34